Financial Performance - The company's revenue for Q1 2025 was ¥118,478,458.16, representing a 2.32% increase compared to ¥115,797,089.07 in the same period last year[5] - Net profit attributable to shareholders decreased by 6.51% to ¥31,212,181.59 from ¥33,384,770.13 year-on-year[5] - Basic earnings per share decreased by 6.06% to ¥0.31 from ¥0.33 in the same period last year[5] - Total operating revenue for the current period reached ¥118,478,458.16, an increase of 2.93% compared to ¥115,797,089.07 in the previous period[21] - Net profit for the current period was ¥31,212,181.59, a decrease of 6.5% from ¥33,384,770.13 in the previous period[22] - Earnings per share (basic) decreased to 0.31 from 0.33, indicating a decline of 6.06%[23] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 87.47%, reaching ¥40,458,787.37 compared to ¥21,581,743.55 in the previous year[5] - Operating cash flow for the current period was CNY 40,458,787.37, a significant increase of 87.6% compared to CNY 21,581,743.55 in the previous period[25] - Total cash inflow from operating activities reached CNY 104,381,799.72, up from CNY 87,021,728.05, reflecting a growth of 19.9%[25] - Cash and cash equivalents at the end of the period totaled CNY 859,080,388.92, down from CNY 944,815,526.11, indicating a decrease of 9.1%[25] - The company reported a net decrease in cash and cash equivalents of CNY 175,401,723.36 for the current period, contrasting with an increase of CNY 8,027,047.49 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,505,934,094.12, a 1.34% increase from ¥1,485,991,744.60 at the end of the previous year[5] - Total liabilities decreased to ¥125,389,912.30 from ¥141,837,087.40, a reduction of 11.6%[19] - The total equity attributable to shareholders increased to ¥1,380,544,181.82 from ¥1,344,154,657.20, reflecting a growth of 2.7%[19] Research and Development - Research and development expenses surged by 120.63% to ¥9,441,180.96, up from ¥4,279,248.99 in the previous year, primarily due to increased employee compensation and external research[9] - Research and development expenses rose significantly to ¥9,441,180.96, compared to ¥4,279,248.99, marking an increase of 107.5%[22] - The company has extended the expected completion date of the R&D center project from March 31, 2025, to September 30, 2025[15] Investments and Projects - The company signed an investment cooperation agreement with the Dongyang Economic Development Zone Management Committee to invest at least RMB 2 billion in the construction of a new pharmaceutical plant[12] - The project for the production line of 200 tons of Atorvastatin Calcium has been changed to a new project with a capacity of 300 tons, responding to market demand[14] - The company has adjusted its fundraising project to prioritize the construction of leading raw material drug production lines to meet growing market needs[14] - The company is actively promoting the construction of the new plant project and will comply with relevant laws and regulations for timely information disclosure[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,872, with the largest shareholder, Zhejiang Haisen Holdings, holding 32.31% of the shares[10] - The company will hold a temporary shareholders' meeting on March 7, 2025, to review the investment cooperation agreement and project updates[12] Other Financial Metrics - Total operating costs amounted to ¥83,568,452.19, up from ¥77,405,038.60, reflecting a rise of 8.3%[21] - The company reported a financial expense of -¥2,554,692.80, an improvement from -¥5,063,404.17 in the previous period[22] - The company experienced a 49.46% increase in selling expenses, totaling ¥2,561,780.56, attributed to higher employee compensation and stock incentives[9] - The company reported a significant increase in investment income, which rose to ¥213,663.34, marking a 100% increase due to higher returns from financial investments[9] - The company reported a 724.29% increase in non-operating income, amounting to ¥501,168.49, primarily due to increased government subsidies unrelated to daily operations[9] Audit Status - The first quarter report was not audited, indicating that the financial data may be subject to further review[27]
海森药业(001367) - 2025 Q1 - 季度财报